March29, 2023

Abstract Volume: 2 Issue: 1 ISSN:

Plasmapheresis and Extracorporeal Immunopharmacotherapy in Scleroderma Treatment

Voinov V.A.*, Ilkovich M.M.1, Khodorik N.A.2, Markov N.V.3, Karchevsky K.S.4, Isaulov O.V.5, Zakharova A.S.6, Voinova Ya.V.7


1,2,3,4,5,6,7. I.P Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

*Corresponding Author: Voinov V.A, I.P Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Received Date:  December 05, 2020

Publication Date:  January 01, 2021

Scleroderma or systemic sclerosis is a systemic autoimmune disease with high morbidity and mortality rate. As a result of vasculopathy and fibrosis, there are not only lesions of the skin, but also several internal organs such as lungs, kidneys, and myocardium. Hyperfunction of fibroblasts with increased collagen biosynthesis underlies generalized fibrosis. The main triggers of vascular lesions are elevated levels of anti-endothelial antibodies, circulating immune complexes, signs of T-lymphocyte activation with high levels of cytokines. Drug therapy is often accompanied by complications and is not always able to prevent the progression of the disease. All this determines the indications for plasmapheresis and in severe cases for extracorporeal immunopharmacotherapy when in addition to removing antibodies and other pathological metabolites there is targeted suppression of lymphocytes activity producing antibodies and cytokines.

Keywords: scleroderma, systemic sclerosis, autoimmune diseases, plasmapheresis, extracorporeal immunopharmacotherapy.

Plasmapheresis and Extracorporeal Immunopharmacotherapy in Scleroderma Treatment


Scleroderma or systemic sclerosis is a systemic autoimmune disease with high morbidity and mortality rate and occurs from 4 to 50 per 100, 000 of the population (1-3). This disease is characterized by fibrosis and vasculopathy of the skin and internal organs (4). Interstitial pulmonary fibrosis with pulmonary hypertension develops in most patients with scleroderma, significantly aggravates the course of the disease, and is one of the main causes of lethal outcomes (5-7). Fibrosis and vasculopathy are the main causes of Raynaud's syndrome development associated with ischemia and ulcers of the terminal phalanges of the fingers (8). This is accompanied by ulcerations of the facial skin and mucosa of the oral cavity (9). Fibrosis with microcirculation disorders damages both the myocardium and heart valves, accompanied by heart failure, arrhythmias, up to sudden cardiac arrest (10). 10-15% of patients develop kidney damage with arterial hypertension, oliguria and thrombotic microangiopathy with a five-year survival rate of up to 50% of patients, despite hemodialysis (11). The gullet can also be involved followed by gastroesophageal reflux development (12). At the same time, bleeding is possible, both gastrointestinal and pulmonary, cerebral and urogenital (13).


Hyperfunction of fibroblasts with increased collagen biosynthesis underlies generalized fibrosis. Peripheral Raynaud's syndrome is an early and characteristic sign of scleroderma and has its internal equivalent in the form of visceral (lungs, heart, and kidneys) Raynaud's syndrome. Spasms in combination with microvascular lesions cause macro digital necrosis, pulmonary hypertension, and myocardial ischemia. The target organ is microcirculation with damage to the endothelium, proliferation of intima and smooth muscles, which is accompanied by microangiopathies and microthromboses. The main triggers of vascular lesions are elevated levels of anti-endothelial antibodies of Willebrand factor and factor VIII. Antibodies against annexin-V protein were detected in patients with ischemic finger necrosis (14).

The very combination of scleroderma with other systemic autoimmune diseases (polymyositis, lupus erythematosus), along with a high frequency of detection of autoantibodies, circulating immune complexes, signs of T-lymphocyte activation with a high level of cytokines, clearly proves the autoimmune nature and pathogenesis of this disease. The blood plasma of these patients contains antibodies to a wide range of nuclear and cytoplasmic antigens. In addition to lesions of the skin itself, there are antibodies against endothelial cells; this fact determines concomitant vascular pathology associated with increased collagen formation by fibroblasts with perivascular disorders in the early stages of the disease. This determines the significant incidence of scleroderma combined with kidney and myocardium damage.


The autoimmune nature of the disease justifies the administration of glucocorticoids, which can reduce the level of autoantibodies and several toxic cytokines (15). However, in addition to well-known complications (Cushing's syndrome, arterial hypertension, diabetes mellitus, osteoporosis), they can promote kidney damage development (16). It is possible to reduce the negative effects of corticosteroids by intravenous administration of immunoglobulins (17). However, such tactics besides their high cost have the danger of transferring viral diseases and allergies. In interstitial lung disease, corticosteroids are combined with cyclophosphamide pulse therapy (18). Mycophenolate mofetil and rituximab are also used (19). However, rituximab can lead to a significant decrease in the diffusion capacity of the lungs (20)

In the case of the kidney damage, angiotensin-converting enzyme inhibitors are used, though, it is not always able to interrupt the progression of kidney failure, requiring hemodialysis and even the kidney transplantation (21). The use of Type V phosphodiesterase inhibitors, endothelin receptor antagonists is also far from being able to stop the progression of the disease, which makes to resort to hematopoietic stem cell transplantation (22, 23). There are attempts to use the photopheresis method when apoptosis occurs during ultraviolet irradiation of lymphocytes and in this form they are returned to circulation (24, 25). In this case, immunosuppression is achieved; however, the accumulated autoantibodies, immune complexes, and other pathological metabolites are not removed.

Apheresis therapy

Insufficient effectiveness and complications of drug therapy suggest the use of efferent therapy, mainly plasmapheresis. With its help, it is possible to remove autoantibodies, immune complexes, cytokines, and other large molecular toxic metabolites from the body (26-28). A good clinical effect was achieved after a course of “programmed” plasmapheresis followed by administration of high doses of immunoglobulins, carried out during the year (29). It was also reported that stable remission was achieved with regular plasmapheresis for 22 years (28). In scleroderma with manifestations of Raynaud's syndrome, plasmapheresis improves hemorheology (rheopheresis), which is especially important for lesions of the fingers (30,31). With predominant damage to the kidneys, especially associated with the development of thrombotic microangiopathy, stabilization of the process can be achieved using plasmapheresis (32-34). Plasmapheresis prevented the progression and interstitial lung disease (35,36).

Extracorporeal Immunopharmacotherapy

A more complete therapeutic effect can be expected with extracorporeal immunopharmacotherapy, being described earlier (37). This is achieved by plasmapheresis with the release of lymphocytes, incubating them with a small dose of corticosteroids and their subsequent return to the circulation. In this case, targeted suppression of their activity occurs without toxic effects on the whole body. Reduced levels of autoantibodies, circulating immune complexes and several cytokines (TNF-α, IL-2, INF-γ) with improved clinical symptoms persisted for at least six months. 

Our own experience covers the treatment of 23 patients with interstitial lung disease on the background of scleroderma, of which 5 underwent only traditional drug therapy, and 18 – combined with plasmapheresis. At the same time, a more controlled remission was achieved. In particular, over 3 years of observation, the diffusion capacity of the lungs decreased only by 1.83%, while in the control group it decreased by 11.0%. Systolic pressure in the pulmonary artery increased by 2.13% to compare with 4.10% in the control group. A more significant decrease in the content of circulating immune complexes was also observed (in 44.4% of patients versus 20.0% in the control group). Also, one of the patients in the control group died, having increasing pulmonary hypertension.


Thus, scleroderma is an autoimmune disease in which, besides the skin, several vital organs (lungs, kidneys, heart) are affected, which determines the severity of the disease with a high level of morbidity and mortality rate. Drug therapy is not always able to delay the disease progression, especially with the involvement of the internal organs. All this also determines indications for plasmapheresis, with help of which autoantibodies and other pathological metabolites can be removed from the body, considering their molecule size that does not allow them to be excreted by the kidneys. In more severe cases, the use of extracorporeal immunopharmacotherapy with targeted suppression of lymphocyte activity is justified, for they are producers of autoantibodies and toxic cytokines.


1.Nikpour M, Stevens WM, Herrick AL, Proudman SM. “Epidemiology of systemic sclerosis”. Best Pract Res Clin Rheumatol 2010; 24 (6): 857-869.

2.Ingegnoli F, Ughi N, Mihai C. “Update on the epidemiology, risk factors, and disease outcome of systemic sclerosis”. Best Pract Res Clin Rheumatol. 2018; 32 (2): 223-240.

3.Zhong L, Pope M, Shen Y et al. “Prevalence and incidence of systemic sclerosis: a systematic review and meta-analysis”. Int J Rheum Dis 2019; 22(12):2096-2107.

4.Wu W, Jordan S, Graf N et al. “Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort”. Ann Rheum Dis 2019; 78 (5): 648-656.

5.Bergamasco A, Hartmann N, Wallace L, Verpillat P. “Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease”. Clin Epidemiol 2019; 11: 257-273.

6.Hoffmann-Vold AM, Fretheim H, Halse AK et al. “Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort”. Am J Respir Crit Care Med 2019; 200 (10): 1258-1266.

7.Saygin D, “Domsic RT Pulmonary arterial hypertension in systemic sclerosis: challenges in diagnosis, screening and treatment”. Open Access Rheumatol 2019; 11: 323-333.

8.Morrisroe K, Stevens W, Sahar J et al. “Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristic, and associated clinical and economic burden”. Arthritis Res Ther 2019; 21: 299.

9.Gomes da Silva GS, Maymone de Melo ML, Leão JC et al. “Oral features of systemic sclerosis: a case-control study”. Oral Dis 2019;25(8): 1995-2002.

10.Nie LY, Wang XD, Zhang T, Xue J. “Cardiac complications in systemic sclerosis: early diagnosis and treatment”. Clin Med J (Engl) 2019; 132(23): 2865-2871.

11.Woodworth TG, Suliman YA, Li W et al. “Scleroderma renal crisis and renal involvement in systemic sclerosis”. Nat Rev Nephrol 2016;12 (11): 678-691.

12.Denton CP, Khanna D. “Systemic sclerosis”. Lancet 2017; 390 (10103): 1685-1699.

13.Michel A, González-Pérez A, Sáez ME, Garcia Rodriguez LA. “Risk of bleeding events among patients with systemic sclerosis and the general population in the UK: a large population-based cohort study”. Clin Rheumatol 2020; 39: 19-26.

14.Sugiwara K, Muro Y. “Anti-annexin V antibodies and digital ischemia in patients with scleroderma”. J Rheumatol 1999; 26 (10): 2168-2172. Almeida AR, Dantas AT, Pereira MC. et al. “Dexamethasone inhibits cytokine production in PBMC from systemic sclerosis patients”. Inflammopharmacology 2019; 27 (4): 723-730.

16.Blagojevic J, Legendre P, Matucci-Cerrinic M, Mouthon L. “Is there today a place for corticosteroids in the treatment of sclerodermia?” Autoimmon Rev 2019; 18 12): 102403.

17.Chaigne B, Rodeia S, Benmostefa N et al.  “Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients”. Autoimmun Rev 2020; 19 (1):102431.

18.Sumida H, Asano Y, Tamaki Z et al. “Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study”. J Dermatol 2018; 45 (12):1425-1433.

19.Fernández-Codina A, Walker KM, Pope JE. “Scleroderma Algorithm Group”. Arthritis Rheumatol 2018; 70(11). 1820-1828.

20.Franzen D, Ciurea A, Bratton DJ et al. “Effect of rituximab on pulmonary function in patients with rheumatoid arthritis”. Pulm Pharmacol Ther 2016; 37: 24-29.

21.Bose N, Chiesa-Vottero A, Chatterjee S. “Scleroderma renal crisis”. Semin Arthritis Rheum 2015; 44 (6): 687-694.

22.Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL. “The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study”. Rheumatology (Oxford) 2017;56(5):844-852.

23.Hughes M, Herrock AL. “Systemic sclerosis”. Br J Hosp Med (Lond) 2019; 80 (9): 530-536.

24.Hassani J, Feldman SR. “Phototherapy in scleroderma”. Dermatol.Ther 2016; (6): 519-553.

25.Papp G, Horvath IF, Gyimesi E et al. “The assessment of immune-regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long-term follow-up study”. Immunol Res 2016; 64 (2): 404-414.

26.Matsuda M. “Plasmapheresis in systemic sclerosis and polymyositis/dermatomyositis”. Nihon Rinsho 2004; 62 (Suppl. 5): 568-571.

27.Voinov VA. Therapeutic apheresis / Constan?a : Celebris, 2016: 403.

28.Harris ES, Meiselman HJ, Moriarty PM, Weiss J. “Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key?” Clin Hemorheol Microcirc 2017; 65 (2): 131-136.

29.Szekanecz Z, Aleksa M, Antal-Szalmas P et al. “Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follw-up of immunopathologic and clinical effects”. Clin Rheumatol 2009; 28 (3): 347-350.

30.Lutze S, Daeschlein G, Konschake W, Jünger M. “Rheopheresis as a causal therapy option for systemic scleroderma (SSc)”. Clin Hemorheol Microcirc 2017; 67 (3-4): 229-240.

31.Korsten P, Müller GA, Rademacher JG et al. “Rheopheresis for digital ulcers and Raynaud’s phenomenon in systemic sclerosis refractory to conventional treatments”. Front Med (Lausanne) 2019; 6: 208.

32.Minami T, Akazawa M, Kanda E, Nonomura Y. “13-year history of scleroderma complicated by renal crisis and thrombotic microangiopathy treated with plasma exchange: a case report”. Nihon Rinsho Meneki Gakkai Kaishi 2015; 38 (2): 116-120.

33.Zanatta E, Polito P, Favaro M et al. “Therapy of scleroderma renal crisis: state of the art” Autoimmun Rev 2018; 17 (9): 882-889.

34.Shimizu T, Iwamoto N, Okamoto M et al. “Scleroderma renal crisis complicated with thrombotic microangiopathy triggered by influenza B virus infection”. Intern Med 2019; 58 (3): 441-445.

35.Nagamura N, Kin S. “Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange”. Nagoya J Med Sci 2016; 78 (3): 329-334.

36.Zhang H, Liang J, Tang X et al. “Sustained benefit from combined plasmapheresis and allogenic mesenchimal stem cells transplantation therapy in systemic sclerosis”. Arthritis Res Ther 2017; 19 (1): 165.

37.Voinov VA, Ilkovich MM, Isaulov OV et al. “Extracorporeal Immunofarmarotherapy of Autoimmune Diseases”. Journal Clinical & Experimental Immunology 2019; 4 (1): 1-5.


Volume 2 Issue 1 January 2021

©All rights reserved by Voinov V.A